Argus’ Jacob Kilstein reiterated a Buy rating on Metlife Inc (NYSE: MET), while lowering the price target from $62 to $54. “Our rating reflects the stock’s attractive valuation, as well as the company’s global initiatives and efforts to return cash to shareholders,. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to: